Objectives
Diabetes mellitus type 2 (T2DM) is associated with an elevated risk of microvascular and macrovascular complications that are the leading cause of morbidity and mortality in this patient population. In 2008, the Food and Drug Administration (FDA) has provided guidance for industry on how to demonstrate that there is no unacceptable increase in cardiovascular risk associated with new antidiabetic drugs for T2DM. Since introduction of the AMNOG in Germany in 2011, the Federal Joint Committee has consistently demanded the analysis of cardiovascular outcomes for new antidiabetics. The objective of this study is to analyze the cardiovascular risk associated with antidiabetics by a literature search.
Methods
To identify long-term outcomes studies, a targeted literature research was conducted in PubMed in 2015, using the search terms Diabetes Mellitus, Type 2/ drug therapy/ epidemiology/ cardiovascular. Included studies were categorized regarding study design, patient-inclusion criteria, pre-existing illness, treatment duration, treatment modus and cardiovascular outcomes. PubMed research was supplemented by additional searches in guidelines in German/English language. 
